The Program includes 27 members from 8 basic and clinical departments within Duke University. Total funding for program members is $21,313,013, of which $13,716,487 is from peer- reviewed sources. A cancer focus is illustrated by $9,448,240 or 68.9% of funding from the NCI, the American Cancer Society or the Department of Defense. From 2004-2008, program members published 628 papers in peer-reviewed journals cited in PubMed. Of these publications, 6% are the result of intra-programmatic collaborations and 33% due to inter-programmatic collaborations.The scientific goals of the Program are to 1) conduct basic, translational and clinical research to elucidate mechanisms of action and of resistance of cancer therapies that target cellular and molecular abnormalities and cell signaling pathways; 2) identify biomarkers, pharmacokinetic/pharmacodynamic endpoints, and molecular and functional imaging parameters that correlate with the anti-tumor activity of cancer therapies and 3) develop innovative methods and strategies for optimized delivery of cancer therapeutics, specifically, small molecules, gene therapy and biologies, 4) design and conduct innovative clinical trials of novel and current therapies that incorporate knowledge of of drug action and resistance, biomarkers, endpoints of response, and advances in pharmacogenomics and pharmacogenetics, and 5) conduct eariy phase discovery, evaluation and optimization of small molecule therapeutics directed against novel therapeutic targets and pathways deregulated in cancer. The organizational goals of the Program are to provide an infrastructure to facilitate the discovery and evaluation of new cancer therapies, enhance pursuit of individual research programs of program members, and facilitate intra- and inter-programmatic collaborative research activities in the area of cancer therapeutics. This will include the organization of retreats, seminar series and related program activities to facilitate interaction and exchange of ideas and information between programs and program members. A major programmatic goal is to promote and enhance training of graduate students, post-doctoral fellows and physician-scientists in basic, translational and clinical sciences relevant to cancer therapeutics. The structure of the program represents a continuum of research activities from the bench to the clinic that provides an ideal environment and opportunity to conduct translational research in an iterative process involving testing findings from the laboratory into hypothesis-driven mechanistic clinical trials, that can generate new questions to be addressed in the laboratory, thereby constantly refining and honing hypotheses that can lead to more effective therapies for cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-38
Application #
8379537
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
38
Fiscal Year
2012
Total Cost
$36,343
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Galaz-Montoya, Monica; Wright, Sara J; Rodriguez, Gustavo J et al. (2017) ?2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem 292:9967-9974
Lanier, Megan L; Park, Hyeri; Mukherjee, Paramita et al. (2017) Formal Synthesis of (+)-Laurencin by Gold(I)-Catalyzed Intramolecular Dehydrative Alkoxylation. Chemistry 23:7180-7184
Shi, Qiong; Liu, Hongliang; Han, Peng et al. (2017) Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol 137:1749-1756
Woyach, Jennifer A; Ruppert, Amy S; Guinn, Daphne et al. (2017) BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 35:1437-1443
Wang, Yanru; Freedman, Jennifer A; Liu, Hongliang et al. (2017) Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. Int J Cancer 141:731-743
Fayanju, Oluwadamilola M; Hall, Carolyn S; Bauldry, Jessica Bowman et al. (2017) Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg 214:666-671
Leu, David; Spasojevic, Ivan; Nguyen, Huy et al. (2017) CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5. Redox Biol 12:864-871
Sauer, Scott J; Tarpley, Michael; Shah, Imran et al. (2017) Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis 38:252-260
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672

Showing the most recent 10 out of 480 publications